Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
185.7 EUR | +0.42% |
|
+1.31% | +20.48% |
05:38am | India's JPMorgan bond index entry to suck $11 billion from S.Africa, Poland and Thailand | RE |
06-25 | Biotech Firm Clario Eyes IPO Early in 2025 | MT |
Strengths
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
Ratings chart - Surperformance
Sector: Banks
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+20.48% | 569B | - | ||
+16.96% | 308B | C+ | ||
+20.68% | 259B | C+ | ||
+24.95% | 188B | B- | ||
+28.52% | 172B | B- | ||
+8.10% | 160B | C+ | ||
-0.75% | 156B | B- | ||
+8.39% | 150B | B- | ||
+13.64% | 143B | C+ | ||
+23.29% | 118B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- JPM Stock
- CMC Stock
- Ratings JPMorgan Chase & Co.